Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial

Overview of attention for article published in The Lancet, September 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 11 news outlets
blogs: 1 blog
twitter: 17 X users
patent: 7 patents

reddit: 2 Redditors
guideline: 1 clinical guideline source
podcasts: 2 podcasts

Readers on

mendeley: 74 Mendeley

So far, Altmetric has seen 17 X posts from 17 X users, with an upper bound of 84,763 followers.

Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial - The Lancet https://t.co/jYcB5HLRTF

16/ ADVANCE IV trial of efgartigimod in chronic ITP (neonatal FC receptor inhibitor). RCT vs placebo. Significant increased, sustained platelet counts with efgartigimod. Novel agent class = another weapon without immunosuppressant risk. https://t.co/2Ii…

RT @rheum_showa: FcRn標的薬であるefgartigimodがITPに対し有効であったphase3 RCT: ADVANCE IV（LANCET 2023） 👉FcRn標的薬はFcRn受容体へ結合しIgGとFcRnとの結合を阻害し，FcRn結合しないIgGを…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 13 additional X posts.